Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

Inclusion Criteria:

• Men, 18yrs and older
• Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic)
• Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma

Exclusion Criteria:

• Prior radiotherapy to bone metastases within 4 weeks prior to screening
• any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
• Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.